Evidence map›Paper›PMID 28267561›Full record

ArticleBrain research bulletin2017

Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABA

Bradford D Fischer, Raymond J Schlitt, Bryan Z Hamade, Sabah Rehman, Margot Ernst, Michael M Poe, Guanguan Li, Revathi Kodali, Leggy A Arnold, James M Cook

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain research bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Antinociceptive Effects ofThe Journal of pharmacology and experimental therapeutics · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. The α2,3-selective potentiator of GABAPharmacology, biochemistry, and behavior · 2019
    Article
  11. Article
  12. Article
  13. Synthesis of chiral GABAARKIVOC : free online journal of organic chemistry
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Bradford D FischerCooper Medical School of Rowan University, Department of Biomedical Sciences Camden, NJ 08103, USA. Electronic address: fischerb@rowan.edu.
Raymond J SchlittCooper Medical School of Rowan University, Department of Biomedical Sciences Camden, NJ 08103, USA.
Bryan Z HamadeCooper Medical School of Rowan University, Department of Biomedical Sciences Camden, NJ 08103, USA.
Sabah RehmanMedical University of Vienna, Department of Molecular Neurosciences, 1090 Vienna, Austria.
Margot ErnstMedical University of Vienna, Department of Molecular Neurosciences, 1090 Vienna, Austria.
Michael M PoeUniversity of Wisconsin-Milwaukee, Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, Milwaukee, WI 53201, USA.
Guanguan LiUniversity of Wisconsin-Milwaukee, Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, Milwaukee, WI 53201, USA.
Revathi KodaliUniversity of Wisconsin-Milwaukee, Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, Milwaukee, WI 53201, USA.
Leggy A ArnoldUniversity of Wisconsin-Milwaukee, Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, Milwaukee, WI 53201, USA.
James M CookUniversity of Wisconsin-Milwaukee, Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, Milwaukee, WI 53201, USA.
University of Wisconsin–Milwaukee · USCooper Medical School of Rowan University · USMedical University of Vienna · AT

Funding

SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDSR01MH046851 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 1991 to 2010
$4.4M
Development of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0M
Design of New Therapeutic Agents to Treat SchizophreniaR01MH096463 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2013 to 2017
$1.9M
Targeting System Xc- for the Treatment of AddictionR01DA025617 · NIDA · MARQUETTE UNIVERSITY · PI BAKER, DAVID A, COOK, JAMES M · 2009 to 2010
$1.4M
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3M
Small molecule inhibitors of the vitamin D receptor-coactivator interactionR03DA031090 · NIDA · UNIVERSITY OF WISCONSIN MILWAUKEE · PI ARNOLD, ALEXANDER · 2010 to 2011
$73k
NHLBI NIH HHS R01 HL118561NIDA NIH HHS R01 DA025617NIDA NIH HHS R03 DA031090NIMH NIH HHS R01 MH046851NIMH NIH HHS R01 MH096463NINDS NIH HHS R01 NS076517
6 · The paper itself

Abstract

γ-Aminobutyric acid type A (GABA

Indexed as

AnimalsBenzodiazepinesDiazepamDose-Response Relationship, DrugGABA-A Receptor Agonistsgamma-Aminobutyric AcidHyperalgesiaImidazolesLigandsMaleMiceMice, Inbred C57BLReceptors, GABA-ABenzodiazepinesDiazepamGABA-A Receptor Agonistsgamma-Aminobutyric AcidImidazolesLigandsReceptors, GABA-AAntihyperalgesiaBehaviorBenzodiazepineGABA receptorsPain

Identifiers

PMID28267561
PMCPMC5501353
OpenAlexW2594766804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.